NCT06942351 Effect of Walnuts on Cognitive Function and Gut Microbiome in Older Adults
| NCT ID | NCT06942351 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oregon State University |
| Condition | Aging |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-06-09 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2025-06-09 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to examine the impact of daily consumption of walnuts for 12 weeks on cognitive function, markers of inflammation and oxidative stress, and the gut microbiome in healthy adults age 55 years and older.
Eligibility Criteria
Inclusion Criteria: * Age 55 years or older * Able to hear well enough to understand spoken instructions and questions * Able to see well enough to read and respond to printed instructions and fill out questionnaires (corrective lenses are allowed) * Able to write legibly and move a computer joystick with at least one hand (i.e., no injury or connective tissue or joint disorder that would impair ability to write or make hand movements) * Able to speak, read, and understand English * Score of greater than 79 on water maze learning task * Willing to maintain current eating patterns * Willing and able to complete the cognitive tests * Willing to stop consuming almonds, Brazil nuts, cashews, chestnuts, hazelnuts, macadamia nuts, peanuts, pecans, pistachios, walnuts, persimmons and pomegranates for 14 weeks. - are nuts or contain ellagitannins or ellagic acid - compounds/foods of interest for this study * Willing to limit oak aged wines and spirits to 1 serving/day and limit blackberries (including similar berries like boysenberries, marionberries, and olallieberries), cloudberries, cranberries, currants, elderberries, lingonberries, raspberries, strawberries, wolfberries, other native berries; guava, mango, muscadine grapes, nectarines, peaches, plums, pluots to 1 cup/day for 14 weeks; REMAIN CONSISTENT (consistent intake levels of): Coffee, tea, apple, apricots, blueberries, cherries, grapes (table/common) * Willing to stop probiotic supplements 2 weeks prior to and during the study (14 weeks) Exclusion Criteria: * Consumption of walnuts, pecans, and chestnuts combined greater than 2 oz / week in the past 3 months. * Use of oral antibiotics in the past month * Regular use of oral anti-inflammatory medications in the past month * Nut, wheat, or gluten allergy/intolerance * Pregnant or planning to become pregnant during the study period * Weighs less than 110 pounds * Diagnosis of sickle cell disease * Susceptibility to motion sickness * Consumes 3 or more alcoholic drinks daily * History of smoking tobacco products, including e-cigarettes and vaporizers in the past 2 years (smokeless tobacco use not exclusionary) * Use of psilocybin or cannabis products (including CBD-only products) in the past 2 years * Current treatment for alcohol or other substance use disorder * History of heart attack, heart failure, or stroke, including transient ischemic attack * History of liver disease or kidney disease requiring dialysis * History of cancer in the past 5 years (Skin cancer that was only surgically treated is not exclusionary) * History of bariatric surgery (e.g., gastric bypass, gastric banding, sleeve gastrectomy, etc.) or disorders (e.g., Crohn's disease, unmanaged celiac disease, ulcerative colitis) * History of thyroid disorder that requires medication, but subject is not taking medication * History of chronic bronchitis or emphysema * Diagnosis of dementia or Alzheimer's disease * History of head injury requiring hospitalization or loss of consciousness \> 5 minutes * History of chronic migraines (for at least 3 months, headache occurring on 15 or more days per month, where at least 8 of those headache days have migraine symptoms) * Blood pressure above 159 (systolic) or 99 (diastolic) mm Hg * Corrected vision worse than 20/50 * Score of less than 10/15 on Ishihara color vision test or diagnosis of color blindness * Score of less than 26/30 on Mini-Mental State Exam * Score of greater than 15 on Center for Epidemiologic Depression survey * History of disease or disorder which causes cognitive impairment, including but limited to: attention-deficit/hyperactivity disorder (ADHD), amyotrophic lateral sclerosis, autism, bipolar disorder, Down's syndrome, encephalitis, epilepsy/seizures, human immunodeficiency virus (HIV), Huntington's disease, Korsakoff's psychosis, multiple sclerosis, Parkinson's disease, or psychotic disorders (e.g., schizophrenia, schizoaffective disorder, schizophreniform disorder) * Current and regular use of any of the following medications: insulin, opioids, anti-seizure medications, psychotropic medications: stimulants, anti-psychotics, or medications that cause daytime drowsiness or difficulty concentrating
Contact & Investigator
Emily Ho, PhD
PRINCIPAL INVESTIGATOR
Oregon State University
Frequently Asked Questions
Who can join the NCT06942351 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, studying Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06942351 currently recruiting?
Yes, NCT06942351 is actively recruiting participants. Contact the research team at emily.ho@oregonstate.edu for enrollment information.
Where is the NCT06942351 trial being conducted?
This trial is being conducted at Corvallis, United States.
Who is sponsoring the NCT06942351 clinical trial?
NCT06942351 is sponsored by Oregon State University. The principal investigator is Emily Ho, PhD at Oregon State University. The trial plans to enroll 80 participants.